Actual price paid and reimbursement ratio after reimbursement by Jisandai (Epclusa) medical insurance
Epclusa (Epclusa/Epclusa) is a fully oral, direct antiviral drug for the treatment of hepatitis C. It has been officially launched in China and is included in the scope of medical insurance reimbursement. Patients can purchase the drug with a doctor's prescription at regular domestic hospitals and pharmacies. The implementation of medical insurance policies has greatly reduced the financial burden on patients, giving more hepatitis C patients the opportunity to receive standardized and effective treatment.
From a price point of view, the domestic market price of Jisandai is about more than 3,000 yuan per box. The specific price may vary depending on region and hospital policies. Under the medical insurance reimbursement policy, the actual payment of most patients will be significantly reduced, and the general reimbursement ratio is between 50% and 70%. After reimbursement, the patient's out-of-pocket payment is about one thousand yuan or even less. It is recommended that patients consult the local medical insurance department or hospital pharmacy to confirm the actual payment amount before taking medication.

In addition to the domestic version of Jisandai, generic drugs abroad, especially in India and Bangladesh, are even cheaper, usually only a few hundred yuan per box. These generic drugs are basically the same as the original drugs in terms of ingredients and efficacy, so they have become a choice that many patients pay attention to. However, it should be noted that purchasing drugs overseas involves the formality of channels and the authenticity of drugs. Patients must be careful to avoid purchasing drugs through illegal channels.
Overall, the post-reimbursement price of Jisandai Medical Insurance has been significantly reduced, which has greatly improved patient accessibility and compliance. For hepatitis C patients, whether they choose original drugs reimbursed by domestic medical insurance or consider cheaper overseas generic drugs, they should make reasonable choices under the guidance of professional doctors to ensure the safety and efficacy of treatment.
Reference materials:https://www.drugs.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)